Back ريبوكستين AZB Reboxetin German Reboxetina Spanish ربوکستین Persian Reboksetiini Finnish Réboxétine French רבוקסטין HE Reboxetina Italian Reboksetyna Polish Reboxetina Portuguese
 (R,R)-(–)-reboxetine (top), (S,S)-(+)-reboxetine (bottom) | |
| Clinical data | |
|---|---|
| Trade names | Edronax, others |
| Pregnancy category |
|
| Routes of administration | By mouth |
| Drug class | Norepinephrine reuptake inhibitor |
| ATC code | |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Bioavailability | ≥94%[2][3] |
| Protein binding | 97–98%[2][3] |
| Metabolism | Liver (CYP3A4-mediated)[2] |
| Elimination half-life | 12–12.5 hours[2][3] |
| Excretion | Urine (78%; 9–10% unchanged)[2][3] |
| Identifiers | |
| |
| CAS Number |
|
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII |
|
| KEGG | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C19H23NO3 |
| Molar mass | 313.397 g·mol−1 |
| 3D model (JSmol) | |
| Chirality | Racemate |
| |
| |
  (what is this?) (verify) | |
Reboxetine, sold under the brand name Edronax among others, is a selective norepinephrine reuptake inhibitor (sNRI) medication marketed as an antidepressant by Pfizer for use in the treatment of major depressive disorder, although it has also been used off-label for panic disorder and attention deficit hyperactivity disorder (ADHD).[4] It is approved for use in many countries worldwide, but has not been approved for use in the United States.[5]
- ^ Anvisa (2023-03-31). "RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial" [Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control] (in Brazilian Portuguese). Diário Oficial da União (published 2023-04-04). Archived from the original on 2023-08-03. Retrieved 2023-08-16.
- ^ a b c d e "PRODUCT INFORMATION EDRONAX® Reboxetine mesilate" (PDF). TGA eBusiness Services. Pfizer Australia Pty Ltd. 17 October 2012. Retrieved 10 November 2013.
- ^ a b c d Holm KJ, Spencer CM (July 1999). "Reboxetine". CNS Drugs. 12 (1): 65–83. doi:10.2165/00023210-199912010-00006. S2CID 72813017.
- ^ Reboxetine Mesilate. The Royal Pharmaceutical Society of Great Britain. 8 November 2011. Retrieved 10 November 2013.
{{cite book}}:|work=ignored (help) - ^ Eyding D, Lelgemann M, Grouven U, Härter M, Kromp M, Kaiser T, Kerekes MF, Gerken M, Wieseler B (October 2010). "Reboxetine for acute treatment of major depression: systematic review and meta-analysis of published and unpublished placebo and selective serotonin reuptake inhibitor controlled trials". BMJ. 341: c4737. doi:10.1136/bmj.c4737. PMC 2954275. PMID 20940209.